Treatment of Helicobacter pylori infection 14-day concomitant quadruple therapy versus triple therapy: A parallel double-blind randomized controlled trial

被引:0
作者
Loghmari, Mohamed Hichem [1 ]
Aissaoui, Firas [1 ]
Guediche, Arwa [1 ]
Bouhlel, Wided [1 ]
Zakhama, Mejda [1 ]
Chaabene, Nabil B. [1 ]
Rehaiem, Amel [1 ]
Ben Abdeljalil, Nouha [2 ]
Njima, Manel [2 ]
Zakhama, Abdelfetteh [2 ]
Kadri, Yosr [3 ]
Mastouri, Maha [3 ]
Safer, Leila [1 ]
机构
[1] Fattouma Bourguiba Univ Hosp, Dept Hepatogastroenterol, Monastir, Tunisia
[2] Fattouma Bourguiba Univ Hosp, Dept Pathol Anat, Monastir, Tunisia
[3] Fattouma Bourguiba Univ Hosp, Microbiol Lab, Monastir, Tunisia
关键词
breath test; eradication; Helicobacter pylori; quadruple concomitant therapy; triple therapy; 1ST-LINE TREATMENT; CLINICAL-PRACTICE; ERADICATION; MULTICENTER; RESISTANCE;
D O I
10.1002/hsr2.1593
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background and AimsSuccessful Helicobacter pylori (Hp) eradication with the traditional 7-day course of proton pump inhibitor triple therapy is declining. Prolonging therapy to 14 days is associated with better eradication rates. Most learned societies recommend concomitant quadruple therapy (QC) as a first-line alternative therapy for this bacterial infection. The aim of this study is to compare the efficacy and safety of triple therapy (TT) and QC for the eradication of Hp infection.MethodsA parallel double-blind randomized controlled trial was conducted. The diagnosis of Hp infection was made by pathological examination of gastric biopsies. Patients were randomly assigned to two treatment groups: either QC (esomeprazole 80 mg, amoxicillin 2000 mg, clarithromycin 1000 mg, and metronidazole 1000 mg daily) or triple therapy (esomeprazole 80 mg, amoxicillin 2000 mg, and clarithromycin 1000 mg daily in divided doses) for 14 days. The efficacy of the treatment is defined by Hp eradication attested by a negative breath test performed 6 weeks after the completion of treatment. Treatment outcomes were compared using the chi-square test, while binary logistic regression identified predictors of treatment failure.ResultsNinety-two patients were included. Forty-two patients belonged to the QC group and 50 to the TT group. No significant difference was noted between the two groups concerning the rate of Hp eradication either by intention to treat (81% vs. 72% respectively, p = 0.31) or per protocol (81.6% vs. 76.1% respectively, p = 0.54). Likewise, there was no difference between the two groups in terms of tolerance to treatment (59.5% for QC vs. 58% for TT, p = 0.88). No factor has been associated with treatment failure.ConclusionThere was no significant difference in the rate of HP eradication between the QC and the 14-day triple therapy. Neither regimen should be used topically because of their low eradication rates.
引用
收藏
页数:8
相关论文
共 29 条
[21]   Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report [J].
Malfertheiner, Peter ;
Megraud, Francis ;
Rokkas, Theodore ;
Gisbert, Javier P. ;
Liou, Jyh-Ming ;
Schulz, Christian ;
Gasbarrini, Antonio ;
Hunt, Richard H. ;
Leja, Marcis ;
O'Morain, Colm ;
Rugge, Massimo ;
Suerbaum, Sebastian ;
Tilg, Herbert ;
Sugano, Kentaro ;
El-Omar, Emad M. .
GUT, 2022, 71 (09) :1724-1762
[22]   Seroprevalence of Helicobacter pylori among Tunisian blood donors (outpatients), symptomatic patients and control subjects [J].
Mansour, K. B. ;
Keita, A. ;
Zribi, M. ;
Masmoudi, A. ;
Zarrouk, S. ;
Labbene, M. ;
Kallel, L. ;
Karoui, S. ;
Fekih, M. ;
Matri, S. ;
Boubaker, J. ;
Cheikh, I. ;
Chouaib, S. ;
Filali, A. ;
Mami, N. B. ;
Najjar, T. ;
Fendri, C. .
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2010, 34 (01) :75-82
[23]   Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study [J].
Molina-Infante, J. ;
Lucendo, A. J. ;
Angueira, T. ;
Rodriguez-Tellez, M. ;
Perez-Aisa, A. ;
Balboa, A. ;
Barrio, J. ;
Martin-Noguerol, E. ;
Gomez-Rodriguez, B. J. ;
Botargues-Bote, J. M. ;
Gomez-Camarero, J. ;
Huerta, A. ;
Modolell, I. ;
Arino, I. ;
Herranz-Bachiller, M. T. ;
Bermejo, F. ;
McNicholl, A. G. ;
O'Morain, C. ;
Gisbert, J. P. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (06) :581-589
[24]  
Park Hye Yoon, 2017, Korean J Gastroenterol, V70, P176, DOI 10.4166/kjg.2017.70.4.176
[25]   Treatment of Helicobacter pylori infection: Current and future insights [J].
Safavi, Maliheh ;
Sabourian, Reyhaneh ;
Foroumadi, Alireza .
WORLD JOURNAL OF CLINICAL CASES, 2016, 4 (01) :5-19
[26]   Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship [J].
Shiotani, Akiko ;
Roy, Priya ;
Lu, Hong ;
Graham, David Y. .
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
[27]   Prevalence and risk factors of Helicobacter pylori infection in Tunisian children: 1055 children in Cap-Bon (northeastern Tunisia) [J].
Siai, K. ;
Ghozzi, M. ;
Ezzine, H. ;
Medjahed, N. ;
Azzouz, M. M. .
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2008, 32 (11) :881-886
[28]   Kyoto global consensus report on Helicobacter pylori gastritis [J].
Sugano, Kentaro ;
Tack, Jan ;
Kuipers, Ernst J. ;
Graham, David Y. ;
El-Omar, Emad M. ;
Miura, Soichiro ;
Haruma, Ken ;
Asaka, Masahiro ;
Uemura, Naomi ;
Malfertheiner, Peter .
GUT, 2015, 64 (09) :1353-1367
[29]   Treatment of Helicobacter pylori infection: a clinical practice update [J].
Zagari, Rocco M. ;
Frazzoni, Leonardo ;
Marasco, Giovanni ;
Fuccio, Lorenzo ;
Bazzoli, Franco .
MINERVA MEDICA, 2021, 112 (02) :281-287